logo
Sign in

LYPHF Stock Price, Chart, Stats & News

Luye Pharma Group Ltd. (LYPHF) does not currently pay a dividend.

1.08B
Market cap
11.71x
Current P/E
11.51x
Forward P/E

LYPHF chart

1M
3M
1Y
5Y
Loading chart...

About

Health care
Sector
Drug Manufacturers - General
Industry

Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation.

Similar securities

Based on sector and market capitalization

Report issue